British Company To Distribute RXi Drug
Westborough-based RXi Pharmaceuticals has signed an agreement with a British company to distribute RXi’s clinical-stage dermal scarring drug in the European Union ahead of regulatory approval.
RXi said in a statement that Ethicor Ltd., a London-based specialty pharmaceuticals company that distributes unlicensed medicines used for unmet clinical needs, now has the distribution rights to RXI-109 in the European Union with the potential to distribute the drug to other parts of the world before the product is registered in the countries covered by the agreement.
EU To Allow RXI As 'Special' Drug
According to RXi, the European Union allows Ethicor to supply RXI-109 prior to regulatory approval based on legislation that allows doctors to request unlicensed medicines to meet the needs of patients under their care. Known as “specials,” these drugs cannot be actively promoted by health care professionals.
“This collaboration is important for health care professionals and patients who can get safe, controlled early access to a developmental drug that could be transformational for patients’ lives,” RXi President and CEO Geert Cauwenbergh said in a statement. “It is also a significant milestone for RXi Pharmaceuticals because, in addition to some possible early revenue, the increased exposure for RXI-109 may be a key in accelerating the development of our drug and in making other companies aware of the business development potential of RXi’s (unique platform).”
The company reported positive results in its second initial-phase study of RXI in the third quarter. The drug works by reducing connective tissue growth factor, a protein that causes abnormal scarring in wounds.
As RXI becomes approved in the countries covered by the agreement, marketing rights will revert back to RXi, according to the company. The agreement does not allow Ethicor to distribute the drug in the United States, Canada, or Mexico.
WBJ Web Partners
Most Recent
Most Recent
0 Comments